Protected: Investors

This post is password protected. To view it please enter your password below:

Password:

Latest News
- Post & Courier Feature: Local tech firms can face uphill climb to win over investors Posted on: Mar 18, 2012
- FirstString Research profiled as SC Launch! portfolio company Posted on: Aug 15, 2011
- FirstString Research Completes Phase I Clinical Trials Posted on: Sep 08, 2010
- Biotech Startup to Receive $200,000 from SC Launch! at Business Summit Posted on: Nov 04, 2009

About

FirstString, a clinical stage biotech company, is leading the translation of cell-cell communication and cell-cell contact/adhesion science into a pipeline of drugs and medical applications for scar prevention, inflammation reduction, wound healing, and complex tissue regeneration. The company is currently advancing Granexin™ Gel, the topical formulation of a lead peptide, through three Phase II clinical trials for scar reduction and treatment of chronic wounds. Preclinical studies are also being conducted with connexin-based peptides for indications having high unmet therapeutic needs in segments that include ophthamology, central nervous system injuries, cardiac injuries, organ transplants, pulmonary, and oncology.
Contact Us

FirstString Research, Inc.
475-A East Bay Street
Charleston, SC 29403
Ph: 843-860-8372
Fax: 843-720-3835
[email protected]